A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
In many cancers, early stage diagnosis and early treatment offers the best chance of a
prolonged recurrence free- and overall survival. In stage III/IV resectable melanoma, an
opportunity exists to improve outcomes with the addition of neoadjuvant and adjuvant systemic
therapy as an adjunct to surgery. Neoadjuvant clinical trials for resectable but bulky stage
III/IV melanoma allows for the efficient and rapid evaluation of drug activity in humans
utilising multiple clinical endpoints of metabolic, radiological and pathological response;
relapse-free survival; overall survival.